Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data Medical ozone gas insufflation in treating ONJ lesions

Journal of Bone Oncology

Volumn 1, Issue 3, 2012, Pages 81-87

  Ripamonti, C I ^a   Maniezzo, M ^b   Boldini, S ^a   Pessi, M A ^a   Mariani, L ^a   Cislaghi, E ^b  

^a Istituto Nazionale dei Tumori   (Italy)

^b Istituto Nazionale Dei Tumori   (Italy)

Author keywords

Bisphosphonates related osteonecrosis of the jaw (ONJ); Bone sequestrum; Spontaneous necrotic bone expulsion; Surgery; Topical medical ozone gas insufflation

Indexed keywords

AZITHROMYCIN; OZONE; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; JAW OSTEONECROSIS; LUNG CANCER; MALE; MULTIPLE CYCLE TREATMENT; MYELOMA; OSTEOPOROSIS; OZONE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 84875631336     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2012.08.001     Document Type: Article

References (54)

1. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104(1):83-93.
2. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. Journal of Clinical Oncology 2006;24(6):945-52.
3. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of Clinical Oncology 2005;23(34):8580-7.
4. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. Journal of Oral and Maxillofacial Surgery 2007;65(7):1328-31.
5. Van den Wyngaert T. Osteonecrosis of the jaw (ONJ) might explain the increased oral surgery risk in cancer patients treated with bisphosphonates. Journal of Evidence Based Dental Practice 2007;7(3):132-5.
6. Henry D, von Moos R, Vadhan-Raj S, Hungria V, Spencer A, Hirsh V, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. European Journal of Cancer Supplements 2009;7(3):12.
7. Stopeck A, Body JJ, Fujiwara Y, Lipton A, Steger GG, Viniegra M, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. European Journal of Cancer Supplements 2009;7(3):2-3.
8. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of Oncology 2012;23:1341-7.
9. Food and Drug Administration, Risk evaluation and mitigation strategies (REMS) BL 125320 Prolia (denosumab). available at: ; [accesssed 23.09.10].
10. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. Journal of Oral and Maxillofacial Surgery 2009;67(Suppl. 5):2-12.
11. Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB. Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist 2009;14:181-91.
12. Stopeck A, Body J, Fujiwara Y, Lipton A, Steger G, Viniegra M, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. European Journal of Cancer Supplements 2009;7:2-3.
13. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. randomized phase lll trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. Journal of Clinical Oncology 2010;28:LCB4507.
14. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Annals of Oncology 2009;20(1):137-45.
15. Tricker N, Dixon R, Garetto L. Cortical Bone Turnover and Mineral Apposition in Dental Bone Mandible. ln: Garetto L, Turner C, Duncan R, Burr D, editors. Bridging the Gap Between Dental and Orthopaedic lmplants. lndianapolis: lndiana University School of Dentistry; 2002. p. 226-7.
16. Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clinical Oral Investigations 2010;14:271-84.
17. Huja SS, Fernandez SA, Hill KJ, Li Y. Remodeling dynamics in the alveolar process in skeletally mature dogs. Anatomical Record A Discoveries in Molecular, Cellular, and Evolutionary Biology 2006;288:1243-9.
18. Woo SB, Hellstein JW, Kalmar Jr. Narrative [corrected]review: bisphospho- nates and osteonecrosis of the jaws. Annals of lnternal Medicine 2006; 144(10):753-61.
19. Barasch A, Cunha-CruzJ, Curro FA, Hujoel P, Sung AH, Vena D, et al. Journal of Dental Research 2011;90(4):439-44.
20. Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E, et al. Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteo- necrosis of the Jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncology 2011;47(3):191-4.
21. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(Suppl. 8): 1588-94.
22. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase lll trials. Pain 1998;78(3):157-69.
23. Body JJ, Diel lJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. lntravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of Oncology 2003; 14(9):1399-405.
24. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, lino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. Journal of Clinical Oncology 2005;23(15):3314-21.
25. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88(5):1082-90.
26. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal- related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98(5):962-9.
27. McCloskey EV, MacLennan lC, Drayson MT, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC working party on Leukaemia in Adults. British Journal of Haematology 1998;100(2):317-25.
28. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology 1993;11(1):59-65.
29. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the zoledronic acid lung cancer and other solid tumors study group. Journal of Clinical Oncology 2003;21(16):3150-7.
30. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of National Cancer Institute 2004;96(11):879-82.
31. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long- term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double- blind, multicenter, comparative trial. Cancer 2003;98(8):1735-44.
32. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. British Journal of Cancer 1997;75(4): 602-5.
33. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bispho- sphonates in multiple myeloma. Journal of Clinical Oncology 2002;20(17): 3719-36.
34. Van Poznak CH, et al. American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. Journal of Clinical Oncology 2011;29(9):1221-7.
35. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. Journal of Clinical Oncology 2007;25(17):2464-72.
36. Terpos E, Sezer O, Croucher PI, Garcia-Sanz R, Boccadoro M, San Miguel J, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European myeloma network. Annals of Oncology 2009;20(8):1303-17.
37. De Marinis F, Eberhardt W, Harper PG, Sureda BM, Nackaerts K, Soerensen JB, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. Journal of Thoracic Oncology 2009;4(10):1280-8.
38. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals of Oncology 2008;19(3):420-32.
39. Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M. International society of geriatric oncology (SlOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. European Journal of Cancer 2007;43(5):852-8.
40. Damato K, Gralow J, Hoff A, Huryn J, Ruggiero S, Schubert M, Toth B, Valero V. Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws. LDA Journal. 2005;64(3):21-4.
41. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery 2007;65(3):369-76.
42. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteone- crosis of the jaw in patients with cancer. Journal of Oncology Practice 2006;2(1):7-14.
43. Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Critical Reviews in Oncology Hematology 2007;62(2):148-52.
44. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis ofthe jaw-2009 update.< http://www. aaoms.org/docs/position-papers/bronj-update.pdf>. [accessed 14.06.10].
45. Montefusco V, Gay F, Spina F, Ambrosini MT, Maniezzo M, Farina L, et al. Antibiotic prophylaxis before dental procedures can reduce onj incidence. Blood (ASH Annual Meeting Abstracts) 2007;110(11):3613.
46. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology 2009;20(1):117-20.
47. Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficay and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Preliminary results of a phase I-II study. Oral Oncology 2011;47:185-90.
48. Bocci V. Ozone as Janus: this controversial gas can be either toxic or medically useful. Mediators of Inflammation 2004;13(1):3-11.
49. Grigor'ian AS, Grigor'iants LA, Guchetl MN. [Experimental-morphological study of the anti-inflammatory action of ozone-perfluorane complex application]. Stomatologiia (Mosk) 2008;87(2):4-9.
50. Agrillo A, Petrucci MT, Tedaldi M, Mustazza MC, Marino SM, Gallucci C, et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws. Journal of Craniofacial Surgery 2006;17(6):1080-3.
51. Agrillo A, Sassano P, Rinna C, Priore P, Iannetti G. Ozone therapy in extractive surgery on patients treated with bisphosphonates. Journal of Craniofacial Surgery 2007;18(5):1068-70.
52. Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. Journal of Craniofacial Surgery 2007;18(5):1071-5.
53. Petrucci MT, Gallucci C, Agrillo A, Mustazza MC, Foa R. Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica 2007;92(9):1289-90.
54. Simon R. Optimal two-stage designs for phase ll clinical trials. Controlled Clinical Trials 1989;10(1):1-10.